UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
August 4, 2004
---------------------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
------------ ------------- --------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrant's telephone number, including area code)
Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The Registrant issued on August 4, 2004, a press release announcing
that the exclusive right to negotiate a license from the Registrant's wholly
owned subsidiary, Elite Laboratories, Inc., for the Registrant's proprietary
abuse resistance technology for oxycodone, previously granted to Purdue Pharma
L.P., has lapsed and as a result Registrant's intention to resume negotiations
as to a license with other companies.
A copy of Registrant's press release is attached as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
99.1. Press Release, dated August 4, 2004
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: August 4, 2004
ELITE PHARMACEUTICALS, INC.
By: /s/ Bernard Berk
---------------------------------
Name: Bernard Berk
Title: Chief Executive Officer